Table 3.
Mean outcome scores, stratified by APOE status.*
| APOE ε4 Noncarriers | APOE ε4 Carriers | |||||
|---|---|---|---|---|---|---|
| In person (n=88) |
Phone (n=86) |
Difference (99% CI) |
In person (n=44) |
Phone (n=39) |
Difference (99% CI) |
|
| 12-mo outcomes | ||||||
| BAI | 3.4 | 3.1 | −0.3 (−1.8 to 1.2) | 4.1 | 4.3 | 0.2 (−2.8 to 3.1) |
| CES-D | 6.0 | 6.5 | 0.6 (−1.8 to 2.9) | 6.8 | 9.2 | 2.4 (−2.6 to 7.4) |
| IES | 2.8 | 2.0 | −0.8 (−3.0 to 1.4) | 3.7 | 7.1 | 3.4 (−2.8 to 9.7) |
| IGT distress | 3.8 | 3.1 | −0.7 (−3.3 to 1.8) | 5.6 | 6.4 | 0.8 (−4.2 to 5.8) |
| IGT positive | 12.0 | 13.5 | 1.5 (−1.3 to 4.4) | 15.0 | 15.9 | 0.9 (−2.8 to 4.6) |
| Full recall | 28.6% | 44.4% | 2.1 (0.9 to 5.0)† | 47.4% | 52.4% | 1.2 (0.4 to 3.7)† |
| Positive subjective impact | 76.1% | 72.2% | 0.8 (0.3 to 2.0)† | 47.4% | 37.5% | 0.6 (0.2 to 2.2)† |
| 6-mo outcomes | ||||||
| BAI | 3.2 | 2.5 | −0.6 (−1.9 to 0.6) | 2.9 | 3.4 | 0.5 (−1.8 to 2.7) |
| CES-D | 5.1 | 5.9 | 0.8 (−1.4 to 3.0) | 5.7 | 6.6 | 0.9 (−3.0 to 4.8) |
| IES | 3.0 | 2.6 | −0.4 (−2.9 to 2.2) | 5.5 | 6.8 | 1.3 (−4.0 to 6.6) |
| IGT distress | 3.5 | 3.3 | −0.2 (−2.3 to 2.0) | 5.5 | 7.5 | 2.0 (−2.6 to 6.6) |
| IGT positive | 9.7 | 11.1 | 1.4 (−1.3 to 4.2) | 14.4 | 12.8 | −1.5 (−5.0 to 1.9) |
| Full recall | 41.2% | 54.5% | 1.7 (0.8 to 3.8)† | 47.4% | 47.4% | 1.1 (0.3 to 3.4)† |
| Positive subjective impact | 81.5% | 76.2% | 0.7 (0.3 to 2.0)† | 44.4% | 33.3% | 0.6 (0.2 to 2.2)† |
| 6-wk outcomes | ||||||
| BAI | 2.8 | 2.9 | 0.0 (−1.2 to 1.2) | 2.9 | 3.8 | 0.9 (−0.9 to 2.6) |
| CES-D | 4.9 | 6.7 | 1.8 (−0.6 to 3.0) | 4.4 | 5.9 | 1.6 (−1.3 to 4.4) |
| IES | 2.7 | 3.3 | 0.6 (−1.8 to 3.0) | 6.3 | 6.6 | 0.3 (−5.4 to 6.0) |
| IGT distress | 3.8 | 4.0 | 0.3 (−2.0 to 2.5) | 6.4 | 7.3 | 0.9 (−3.8 to 5.6) |
| IGT positive | 7.7 | 8.8 | 1.1 (−1.4 to 3.5) | 12.1 | 13.8 | 1.6 (−2.0 to 5.2) |
| Full recall | 60.0% | 63.0% | 1.1 (0.5 to 2.6)† | 50.0% | 50.0% | 1.0 (0.3 to 3.1)† |
| Positive subjective impact | 73.0% | 68.8% | 0.8 (0.3 to 2.0)† | 41.2% | 23.1% | 0.4 (0.1 to 1.5)† |
| Time-averaged outcomes | ||||||
| BAI | 3.1 | 2.8 | −0.3 (−1.8 to 1.2) | 4.1 | 4.3 | 0.2 (−2.6 to 3.1) |
| CES-D | 5.3 | 6.4 | 1.0 (−0.7 to 2.8) | 5.6 | 7.1 | 1.6 (−1.4 to 4.6) |
| IES | 2.8 | 2.6 | −0.2 (−2.2 to 1.7) | 5.0 | 6.8 | 1.8 (−3.5 to 7.0) |
| IGT distress | 3.7 | 3.5 | −0.2 (−2.3 to 1.9) | 5.9 | 7.0 | 1.2 (−3.2 to 5.6) |
| IGT positive | 9.6 | 11.0 | 1.3 (−0.9 to 3.6) | 13.8 | 14.1 | 0.3 (−2.6 to 3.2) |
| Full recall | 44.4% | 54.5% | 1.6 (0.8 to 3.1)† | 47.4% | 50.0% | 1.1 (0.4 to 2.8)† |
| Positive subjective impact | 76.7% | 72.2% | 0.8 (0.4 to 1.7)† | 44.4% | 33.3% | 0.6 (0.2 to 1.5)† |
*
Scores were estimated using generalized estimating equations with log link and γ distribution for continuous measures and with logit link and binomial distribution for dichotomized measures, with adjustment for corresponding baseline values and the genetic counselor providing disclosure.
†
Differences for dichotomized outcomes, full recall and positive subjective impact, represent odds ratios (i.e, the odds of full recall or positive subjective impact following telephone disclosure compared to in-person disclosure).